These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9666938)
1. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Dominguez Cabrera C; Sosa Henríquez M; Traba ML; Alvarez Villafañe E; de la Piedra C Osteoporos Int; 1998; 8(2):147-51. PubMed ID: 9666938 [TBL] [Abstract][Full Text] [Related]
2. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. Ebeling PR; Peterson JM; Riggs BL J Bone Miner Res; 1992 Nov; 7(11):1243-50. PubMed ID: 1466250 [TBL] [Abstract][Full Text] [Related]
3. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W; Muley T; Herb KP; Schmidt-Gayk H Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610 [TBL] [Abstract][Full Text] [Related]
4. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis. Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575 [TBL] [Abstract][Full Text] [Related]
5. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479 [TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213 [TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family. Hernández MV; Peris P; Guañabens N; Alvarez L; Monegal A; Pons F; Ponce A; Muñoz-Gómez J Calcif Tissue Int; 1997 Jul; 61(1):48-51. PubMed ID: 9192513 [TBL] [Abstract][Full Text] [Related]
8. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636 [TBL] [Abstract][Full Text] [Related]
9. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. Hannon R; Blumsohn A; Naylor K; Eastell R J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076 [TBL] [Abstract][Full Text] [Related]
10. Reference intervals for serum concentrations of three bone turnover markers for men and women. Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251 [TBL] [Abstract][Full Text] [Related]
11. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen. Katagiri M; Fukunaga M; Ohtawa T; Harada T World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946 [TBL] [Abstract][Full Text] [Related]
12. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. Kushida K; Takahashi M; Kawana K; Inoue T J Clin Endocrinol Metab; 1995 Aug; 80(8):2447-50. PubMed ID: 7629240 [TBL] [Abstract][Full Text] [Related]
13. Biochemical markers as predictors of rates of bone loss after menopause. Rogers A; Hannon RA; Eastell R J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690 [TBL] [Abstract][Full Text] [Related]
14. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934 [TBL] [Abstract][Full Text] [Related]
15. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy? Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729 [TBL] [Abstract][Full Text] [Related]
16. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139 [TBL] [Abstract][Full Text] [Related]
17. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. Koizumi M; Yonese J; Fukui I; Ogata E J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449 [TBL] [Abstract][Full Text] [Related]
18. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638 [TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. Díaz Diego EM; Díaz Martín MA; de la Piedra C; Rapado A Horm Metab Res; 1995 Mar; 27(3):151-4. PubMed ID: 7607606 [TBL] [Abstract][Full Text] [Related]
20. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women. Botella S; Restituto P; Monreal I; Colina I; Calleja A; Varo N J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]